Bashir Al Hussein Al Awamlh

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Editorial Comment

Muscle Invasive Bladder Cancer

Top Venues

Current oncology reports

The Journal of urology

JCO global oncology

Translational andrology and urology

This page only lists publications with an associated author ORCID identifier.

Publications

Mary O Strasser, Bashir Al Hussein Al Awamlh
Editorial Comment. The Journal of urology 212 (1) (2024)
Mary O Strasser, Neal A Patel, Bashir Al Hussein Al Awamlh
Editorial Comment. The Journal of urology (2024)
Mary O Strasser, Neal A Patel, Bashir Al Hussein Al Awamlh
Editorial Comment. The Journal of urology (2024)
Mary O Strasser, Bashir Al Hussein Al Awamlh
Editorial Comment. The Journal of urology 212 (1) (2024)
Abdulrahman A Alhajahjeh, Majedah Hmeidan, Mus'ab Elatrsh, Faris Al-Abbadi, Diala Kakish, Razan Sukerji, Mohammad Salah, Bashir Al Hussein Al Awamlh, David I Lee, Mohammed Shahait
Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges. JCO global oncology 10 (2024)
Olutiwa A Akinsola, Ruchika Talwar, Avi Baskin, Amy N Luckenbaugh, Bashir Al Hussein Al Awamlh
Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer. Translational andrology and urology 13 (6) (2024)
Abdulrahman A Alhajahjeh, Majedah Hmeidan, Mus'ab Elatrsh, Faris Al-Abbadi, Diala Kakish, Razan Sukerji, Mohammad Salah, Bashir Al Hussein Al Awamlh, David I Lee, Mohammed Shahait
Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges. JCO global oncology 10 (2024)
Olutiwa A Akinsola, Ruchika Talwar, Avi Baskin, Amy N Luckenbaugh, Bashir Al Hussein Al Awamlh
Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer. Translational andrology and urology 13 (6) (2024)
Mary O Strasser, Bashir Al Hussein Al Awamlh
Editorial Comment. The Journal of urology (2024)
Abdulrahman A Alhajahjeh, Majedah Hmeidan, Mus'ab Elatrsh, Faris Al-Abbadi, Diala Kakish, Razan Sukerji, Mohammad Salah, Bashir Al Hussein Al Awamlh, David I Lee, Mohammed Shahait
Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges. JCO global oncology 10 (2024)
Brian D Cortese, Stacie B Dusetzina, Amy N Luckenbaugh, Bashir Al Hussein Al Awamlh, C J Stimson, Daniel A Barocas, David F Penson, Sam S Chang, Ruchika Talwar
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports 25 (2) (2022)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports 25 (2) (2022)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports 25 (2) (2022)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports (2022)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports 25 (2) (2022)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports 25 (2) (2022)
Bashir Al Hussein Al Awamlh, Sam S Chang
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Current oncology reports (2022)
Bashir Al Hussein Al Awamlh, Karla V Ballman, Xiaoyue Ma, Jim C Hu, Jonathan E Shoag
Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States. Prostate cancer and prostatic diseases 23 (4) (2020)